CARLINO, G.; FORNARO, M.; SANTO, L.; BUCCI, R.; SEMERARO, A.; QUARTA, L.; D’ONOFRIO, F.; MARSICO, A.; ZUCCARO, C.; FALAPPONE, P.; MAZZOTTA, D.; CANTATORE, F.; MURATORE, M.; IANNONE, F. Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE). Reumatismo, v. 71, n. 1, p. 24-30, 1 abr. 2019.